Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
18,317 results
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: Complete Statistical AnalysisIndependent statistical analysis of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LDOTIndependent statistical analysis of Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00385684).
- LDP0114Independent statistical analysis of Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LEAD-2Independent statistical analysis of To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together:…
- LEADER 75Independent statistical analysis of Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LEADER®Independent statistical analysis of Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- LEADER7Independent statistical analysis of Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LEAPIndependent statistical analysis of AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05089708).
- LEAPIndependent statistical analysis of A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD): primary endpoint results, effect estimate with…
- LEAPIndependent statistical analysis of Lifestyle Enhancement for ADHD Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03690674).
- LEAPIndependent statistical analysis of Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LEAP-001Independent statistical analysis of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAP-007Independent statistical analysis of Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] -…
- LEAP-OnIndependent statistical analysis of Persistence of Oral Tolerance to Peanut: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366846).
- LEAP2Independent statistical analysis of Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAPSIndependent statistical analysis of Locomotor Experience Applied Post Stroke Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00243919).
- Learn, Engage, Act, Process (LEAP) for MOVE!: Complete Statistical AnalysisIndependent statistical analysis of Learn, Engage, Act, Process (LEAP) for MOVE!: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02825680).
- Learning Direct Laryngoscopy Using a McGrath Video Laryngoscope as Direct Versus Indirect Laryngoscope: Complete Statistical AnalysisIndependent statistical analysis of Learning Direct Laryngoscopy Using a McGrath Video Laryngoscope as Direct Versus Indirect Laryngoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Learning Impairments Among Survivors of Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576472).
- Learning Skills Together Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Learning Skills Together Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04428034).
- LED Therapy for the Treatment of Concussive Brain Injury: Complete Statistical AnalysisIndependent statistical analysis of LED Therapy for the Treatment of Concussive Brain Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02383472).
- Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval,…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: Complete Statistical AnalysisIndependent statistical analysis of LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02494921).
- LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Leflunomide 20 mg Tablets, Non-Fasting: Complete Statistical AnalysisIndependent statistical analysis of Leflunomide 20 mg Tablets, Non-Fasting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00834405).
- Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: Complete Statistical AnalysisIndependent statistical analysis of Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Left Lateral Position Versus Supine Position in Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Left Lateral Position Versus Supine Position in Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06664762).
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): Complete Statistical AnalysisIndependent statistical analysis of Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00738972).
- LEFTBASHIndependent statistical analysis of Left Bundle Area Versus Selective His Bundle Pacing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04093414).
- LEGIT_MC_EVCDAIndependent statistical analysis of AI-based Medical Device Validation for Early Melanoma Detection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06221397).
- LEIAIndependent statistical analysis of Lisdexamfetamine's Effect In ADHD in the Brain and Cognition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170298).
- Lemborexant Shift Work Treatment Study: Complete Statistical AnalysisIndependent statistical analysis of Lemborexant Shift Work Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05344443).
- LEMTRADA-ITPIndependent statistical analysis of Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).
- Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: primary…
- Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759603).
- Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…